Unknown

Dataset Information

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.


ABSTRACT:

Background

Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival. Transarterial chemoembolization (TACE) controls tumour growth in the treated HCC nodule, however, the risk of tumour development in the untreated liver is increased by simultaneous release of neo-angiogenic factors. Due to its anti-angiogenic effects, Sorafenib delays the progression of HCC. Aim of this study was to determine whether combination of TACE and Sorafenib improves tumour control in HCC patients on waiting list for LT.

Methods

Fifty patients were randomly assigned on a 1:1 ratio in double-blinded fashion at four centers in Germany and

SUBMITTER: Hoffmann K 

PROVIDER: S-EPMC4449604 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature